Vizora日本語

Cyfuse BiomedicalCyfuse Biomedical K.K.4892東証グロース医薬品FY ending Dec 2025, non-consolidated, J-GAAP

Cyfuse Biomedical FY ending Dec 2022 results

Cyfuse Biomedical brought in ¥374.5M in revenue.

It lost about ¥114 for every ¥100 of sales at the operating level.

Revenue changed -47.1% from the prior year, operating profit -702.4%.

Revenue and profit pattern

Turned to a loss

What changed from last year

FY ending Dec 2021 → FY ending Dec 2022

Revenue
-47.1%¥708.2M → ¥374.5M
Gross profit
-57.7%¥570.6M → ¥241.5M
Operating income
-702.4%¥70.6M → -¥425.1M
Operating cash flow
-349.8%¥161.5M → -¥403.6M

Where the money goes

FY ending Dec 2021 → FY ending Dec 2022

Where ¥100 of sales goes

For every ¥100 Cyfuse Biomedical sells, how much goes where, and how much is kept.

FY ending Dec 2022
Cost of sales
¥36
SG&A
¥178
Operating loss
¥114
Net loss
¥127

Annual margin trends

Gross margin64.5%
FY ending Dec 2021: 80.6%80.6%FY ending Dec 2022: 64.5%64.5%FY21FY22
Operating margin-113.5%
FY ending Dec 2021: 10.0%10.0%FY ending Dec 2022: -113.5%-113.5%FY21FY22
Net margin-126.6%
FY ending Dec 2021: 20.2%20.2%FY ending Dec 2022: -126.6%-126.6%FY21FY22

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (4)

  • EDINET (FSA Japan)

    有価証券報告書－第16期(2025/01/01－2025/12/31)

    ID S100XV4M2026-03-27Open

  • EDINET (FSA Japan)

    有価証券報告書－第15期(2024/01/01－2024/12/31)

    ID S100VGO72025-03-26Open

  • EDINET (FSA Japan)

    有価証券報告書－第14期(2023/01/01－2023/12/31)

    ID S100T55F2024-03-27Open

  • EDINET (FSA Japan)

    有価証券報告書－第13期(2022/01/01－2022/12/31)

    ID S100QGWF2023-03-28Open

Extracted from XBRL: 40 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image